Since 1998, various respiratory syncytial virus (RSV) monoclonal antibody (mAb) therapies have been approved to prevent serious lower respiratory tract disease caused by RSV in young children.
Over the past two years, a single-dose, long-acting mAb designed to protect infants has been approved in Canada, Europe, and the USA.
As of March 2024, among females with an infant less than 8 months, 41.3% reported that their infant received an approved mAbs.
Read More
